BR0214363A - Anticorpo, uso de um anticorpo, medicamento, método de fabricação de um medicamento e pacote farmacêutico para o tratamento de infecção - Google Patents

Anticorpo, uso de um anticorpo, medicamento, método de fabricação de um medicamento e pacote farmacêutico para o tratamento de infecção

Info

Publication number
BR0214363A
BR0214363A BR0214363-1A BR0214363A BR0214363A BR 0214363 A BR0214363 A BR 0214363A BR 0214363 A BR0214363 A BR 0214363A BR 0214363 A BR0214363 A BR 0214363A
Authority
BR
Brazil
Prior art keywords
antibody
drug
infection
manufacture
treatment
Prior art date
Application number
BR0214363-1A
Other languages
English (en)
Inventor
James Peter Burnie
Ruth Christine Matthews
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Publication of BR0214363A publication Critical patent/BR0214363A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"ANTICORPO, USO DE UM ANTICORPO, MEDICAMENTO, MéTODO DE FABRICAçãO DE UM MEDICAMENTO E PACOTE FARMACêUTICO PARA O TRATAMENTO DE INFECçãO". A presente invenção diz respeito a novos anticorpos, medicamentos, pacotes farmacêuticos, métodos de fabricação de medicamentos e métodos para o tratamento de infecções por microorganismo, particularmente para o tratamento de infecções estafilocócicas tais como infecções pelo S. aureus, incluindo infecções MRSA.
BR0214363-1A 2001-11-22 2002-11-13 Anticorpo, uso de um anticorpo, medicamento, método de fabricação de um medicamento e pacote farmacêutico para o tratamento de infecção BR0214363A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0127983.5A GB0127983D0 (en) 2001-11-22 2001-11-22 Treatment of micro-organism infection
PCT/GB2002/005135 WO2003046007A2 (en) 2001-11-22 2002-11-13 Treatment of micro-organism infection

Publications (1)

Publication Number Publication Date
BR0214363A true BR0214363A (pt) 2004-10-26

Family

ID=9926237

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214363-1A BR0214363A (pt) 2001-11-22 2002-11-13 Anticorpo, uso de um anticorpo, medicamento, método de fabricação de um medicamento e pacote farmacêutico para o tratamento de infecção

Country Status (18)

Country Link
US (3) US20050118162A1 (pt)
EP (2) EP1446425B1 (pt)
JP (1) JP2005511645A (pt)
CN (2) CN101254304A (pt)
AT (1) ATE427320T1 (pt)
AU (2) AU2002339159B2 (pt)
BR (1) BR0214363A (pt)
CA (1) CA2465072A1 (pt)
DE (1) DE60231825D1 (pt)
DK (1) DK1446425T3 (pt)
ES (1) ES2322756T3 (pt)
GB (1) GB0127983D0 (pt)
NO (2) NO20042604L (pt)
NZ (1) NZ533623A (pt)
PL (1) PL369536A1 (pt)
PT (1) PT1446425E (pt)
RU (1) RU2303460C2 (pt)
WO (1) WO2003046007A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127983D0 (en) * 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
JP5248032B2 (ja) * 2007-04-23 2013-07-31 株式会社Ａｄｅｋａ ケイ素含有化合物、硬化性組成物及び硬化物
JP5248033B2 (ja) * 2007-04-23 2013-07-31 株式会社Ａｄｅｋａ ケイ素含有化合物、硬化性組成物及び硬化物
WO2008132174A1 (en) * 2007-04-27 2008-11-06 Novartis Ag An immunoglobulin composition
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
BRPI1010911A2 (pt) * 2009-05-18 2019-09-24 Julius Maximilians Univ Wuerzburg De/De "anticorpos ou fragmentos destes direcionados contra um epitopo de staphylococcus aureus"
SG10201704269RA (en) * 2009-07-15 2017-06-29 Aimm Therapeutics Bv Gram-positive bacteria specific binding compounds
WO2011084882A2 (en) * 2010-01-05 2011-07-14 Contrafect Corporation Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
EP2627292B1 (en) 2010-10-15 2018-10-10 Clearside Biomedical, Inc. Device for ocular access
US20130273607A1 (en) * 2010-10-20 2013-10-17 Medimmune, Llc Methods for processing inclusion bodies
SG10201702674PA (en) 2013-05-03 2017-06-29 Clearside Biomedical Inc Apparatus and methods for ocular injection
RU2572341C2 (ru) * 2013-09-20 2016-01-10 Федеральное государственное бюджетное учреждение Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе Российской академии медицинских наук (ФГБУ "НИИНА" РАМН) АНТИБИОТИК ИНА 5812, ШТАММ-ПРОДУЦЕНТ Streptomyces roseoflavus ИНА-Ас-5812 И СПОСОБ ПОЛУЧЕНИЯ АНТИБИОТИКА
EP3452165A1 (en) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
EP3496680A1 (en) 2016-08-12 2019-06-19 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1996007430A1 (en) * 1994-09-06 1996-03-14 Galagen, Inc. Therapeutic treatment of clostridium difficile associated diseases
GB9614274D0 (en) * 1996-07-06 1996-09-04 Univ Manchester Treatment and diagnosis of infections of gram positive cocci
GB9806762D0 (en) 1998-03-31 1998-05-27 Neutec Pharma Plc Treatment and diagnosis of staphylococcal infections
GB0127983D0 (en) * 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection

Also Published As

Publication number Publication date
PT1446425E (pt) 2009-07-01
US20070202116A1 (en) 2007-08-30
NZ533623A (en) 2005-12-23
WO2003046007A2 (en) 2003-06-05
NO20042604L (no) 2004-06-21
AU2002339159B2 (en) 2008-06-05
EP1446425B1 (en) 2009-04-01
ES2322756T3 (es) 2009-06-26
US20050118162A1 (en) 2005-06-02
GB0127983D0 (en) 2002-01-16
US20080171054A1 (en) 2008-07-17
NO20081575L (no) 2004-06-21
ATE427320T1 (de) 2009-04-15
AU2008212001A1 (en) 2008-09-25
RU2303460C2 (ru) 2007-07-27
EP1446425A2 (en) 2004-08-18
JP2005511645A (ja) 2005-04-28
DK1446425T3 (da) 2009-07-20
CA2465072A1 (en) 2003-06-05
CN1589280A (zh) 2005-03-02
CN100371348C (zh) 2008-02-27
EP1964851A1 (en) 2008-09-03
PL369536A1 (en) 2005-05-02
RU2004118716A (ru) 2005-03-27
CN101254304A (zh) 2008-09-03
AU2002339159A1 (en) 2003-06-10
DE60231825D1 (de) 2009-05-14
WO2003046007A3 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
NO20081575L (no) Behandling av mikroorganismeinfeksjoner
DE60224508D1 (de) Wti-modifiziertes peptid
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
NO20033918D0 (no) Ny anvendelse av peptidklasse av forbindelser for behandling av allodyni eller andre typer av kronisk smerte eller fantomsmerte
DK1969003T3 (da) Anvendelser af et neurotrofisk faktor-protein
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
HUP0500039A2 (hu) Vakcina és eljárás mozgatóneuron-betegségek kezelésére
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
FI956050A0 (fi) Biologisesti aktiiviset vasopressiinianalogit
HUP0001458A2 (hu) Specifikus hasnyálmirigy lipáz inhibitor hatású peptidek, ezeket tartalmazó gyógyszerkészítmények és diagnosztikai reagensek, valamint ezek alkalmazása
DE60231649D1 (de) Mittel zur behandlung von augentrockenheit und damit zusammenhängenden erkrankungen
HUP0202931A2 (hu) Egy gyógyszerészetileg hatásos összetétel és a beadására szolgáló készülék
BR9712033A (pt) Composição farmacêutica para tratamento de doenças virais.
SE9700244D0 (sv) Novel antibacterial protein
HUP0300787A2 (hu) Új interferon a sclerosis multiplex kezelésére
KR900011477A (ko) 항-트립타아제 항체 및 이것을 사용한 후천성 면역결핍증 치료용 조성물
WO2001090139A3 (en) A ligand for enhancing oral and cns delivery of biological agents
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
NO963143L (no) Oral legemiddelform inneholdende colestipol som bærer med sure virkestoffer og fremgangsmåte ved fremstilling av denne
EA201000501A1 (ru) Фармацевтическая композиция, содержащая не обладающий нейротоксичностью активатор плазминоген для лечения удара
DE60022995D1 (de) Impfstoff
WO2003029290A1 (fr) Transporteur de medicament et son utilisation
MY143402A (en) Preparations used in the treatment and prophilaxis of mycobacterial infections

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NEUTEC PHARMA LTD. (GB)

Free format text: ALTERADO DE: NEUTEC PHARMA PLC

B25G Requested change of headquarter approved

Owner name: NEUTEC PHARMA LTD. (GB)

Free format text: SEDES ALTERADAS CONFORME SOLICITADO NA PETICAO NO 020080104515/RJ DE 30/07/2008.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2162 DE 12/06/2012.